library.onepin.app/thymopentin Peptide Education Library
Education only, not medical advice 21+ Every dose is an example to finalize with a licensed provider

OnePin Peptide Library · Immune

Immune Peptide Not FDA-approved · investigational

Thymopentin

Thymopoietin Fragment · TP-5

Thymopentin (TP-5) is a synthetic pentapeptide corresponding to amino acids 32-36 (Arg-Lys-Asp-Val-Tyr) of the natural thymic hormone thymopoietin. Thymopoietin is a 49-amino acid polypeptide produced by thymic epithelial cells that plays a critical role in T-cell differentiation and immune regulation. Thymopentin retains the full biological activity of the parent hormone in a much smaller, more stable molecule.,Thymopentin works primarily by promoting the differentiation of precursor T-cells into mature, functional T-lymphocytes. It enhances both the number and function of T-cells, modulates cytokine production, and can restore depressed immune function. It has been studied extensively since the 1980s for a range of immunodeficiency conditions.,Thymopentin has been approved in several countries including China and Italy for clinical use in immunodeficiency states. In China, it is widely used as an adjunct therapy for hepatitis B, certain cancers, and recurrent infections. It has not been FDA-approved in the United States but was the subject of multiple clinical trials in the 1980s-1990s, including studies in HIV/AIDS and rheumatoid arthritis.

Quick Start
Route
Subcutaneous (SubQ)
Start low
50mg
Frequency
3x/week
Timing
No specific requirement

SubQ injection, any time of day. 10-20 day courses, 2-3 cycles per year with 4-6 months between courses (Khavinson protocol). Pin alone or with other bioregulators only.

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first
Quick Start
Conservative start
50mg · Subcutaneous (SubQ) · 3x/week
Lowest starting point. Hold about a week to assess tolerance before stepping up.
50mg
3x/week
Intermediate
Immune Modulator
50 mg · SubQ · 3x Weekly
human study · Sundal E & Bolla K 1987, 'Therapy with thymopentin: a clinical overview' (in Immune Regulation by Characterized Polypeptides, Alan R. Liss, pp 121-136)
50 mg
3x Weekly
Reconstitution CalculatorU-100
050100u
Draw to
units
01

How it works

Induces differentiation of immature T-cell precursors (pro-thymocytes) into mature CD4+ and CD8+ T-lymphocytes by mimicking the active site of thymopoietin, promoting expression of T-cell surface markers.,Modulates the balance between T-helper (Th1/Th2) subsets and enhances natural killer (NK) cell activity, improving both cellular immunity and immunosurveillance.,Stimulates production of interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) while suppressing excessive inflammatory cytokine production, creating a balanced immune response.

Induces differentiation of immature T-cell precursors (pro-thymocytes) into mature CD4+ and CD8+ T-lymphocytes by mimicking the active site of thymopoietin, promoting expression of T-cell surface markers.,Modulates the balance between T-helper (Th1/Th2) subsets and enhances natural killer (NK) cell activity, improving both cellular immunity and immunosurveillance.,Stimulates production of interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) while suppressing excessive inflammatory cytokine production, creating a balanced immune response.

02

What to expect

Early
Days 1–7

Days 1-14: Immune cell differentiation processes begin. No clinically noticeable effects in most patients.

03

Evidence

HumanPresent
AnimalPresent
In-vitroPresent
1985Thymopoietin pentapeptide (thymopentin, TP-5) in the treatment of rheumatoid arthritis. A compilation of several short- and longterm clinical studies · Malaise MG et al, Journal of Rheumatology ↗peer reviewed
1996Biological activity and clinical efficacy of intravenous high-dose thymopentin in metastatic melanoma patients · Bernengo MG et al, Cancer Biotherapy & Radiopharmaceuticals ↗peer reviewed
1998Evaluation of clinical efficacy and tolerability of intravenous high dose thymopentin in advanced melanoma patients · Bernengo MG et al, Anticancer Research ↗peer reviewed
1986In vivo immunopotentiating activity of thymopentin in aging humans: increase of IL-2 production · Sergi G et al, Clinical Immunology and Immunopathology ↗peer reviewed
04

Interactions & stacking

What's safe to combine, and what belongs in a separate pin.

Safe & synergistic

BPC-157Tissue repair peptide and immune modulator act through independent biological systems
EpithalonTelomerase activation and T-cell maturation address different aspects of immune aging
N-Acetyl Selank AmidateAnxiolytic peptide and immune peptide have non-overlapping mechanisms
LL-37Antimicrobial peptide and T-cell maturation peptide provide complementary immune defense and regulation

Keep separate

RapamycinRapamycin suppresses T-cell proliferation via mTOR inhibition, directly opposing thymopentin T-cell maturation effects
GHK-CuCopper-peptide may cause metal-catalyzed degradation of thymopentin - do not mix in same syringe
05

Pharmacokinetics

Illustrative plasma concentration · 24 h
Half-life
~30 min
Peak · Tmax
~15-30 min SubQ
Elimination
~2.5 hours (~5x half-life)
Activity
2-3 days (T-cell differentiation signals persist; supports 3x/week dosing schedule)

Storage. Store refrigerated at 2-8C. Reconstituted solution should be used within 14 days.

06

Regulatory status

Approved pharmaceutical in China and Italy for immunodeficiency states. Not FDA-approved in the US. Investigated in US clinical trials in the 1980s-1990s.

Put it to work

Calculate, log & track

Open Thymopentin straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open Thymopentin in the app →

Go deeper

The guide & community

The complete Thymopentin walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗
Open in app Community